Abdul Karzai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdul Karzai has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Jun Dunbar
Human Oncology and Pathogenesis Program and Leukemia service Memorial Sloan Kettering Cancer Center New York NY USA
28 shared publications - Julie L. Yang
Human Oncology and Pathogenesis Program and Leukemia service Memorial Sloan Kettering Cancer Center New York NY USA
28 shared publications - Mirko Farina
Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Science, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy
28 shared publications - Richard Patrick Koche
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
28 shared publications - Robert L. Bowman
Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
28 shared publications - Ross L. Levine
Memorial Sloan Kettering Cancer Center
28 shared publications
Latest Publications
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
ATAC-Seq analysis - MPN vs. TAM
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
ATAC-Seq analysis - MPN vs. TAM
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Patient characteristics for scATAC-Seq
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Phenotypic characterization and Jak2V617F oncogenic dependency in the setting of concomitant Tet2 loss
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Phenotypic characterization and Jak2V617F oncogenic dependency in the setting of concomitant Tet2 loss
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Functional characterization of Jak2RL knock-in/knock-out in vivo
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Functional characterization of Jak2RL knock-in/knock-out in vivo
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Assessment of tamoxifen toxicity on Jak2RL knock-in cells
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Assessment of tamoxifen toxicity on Jak2RL knock-in cells
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Differential responses of Jak2V617F deletion compared to JAK inhibitor therapy in vivo
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Differential responses of Jak2V617F deletion compared to JAK inhibitor therapy in vivo
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Effects of Jak2V617F deletion on MPN stem cell fitness and disease transplantability
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Effects of Jak2V617F deletion on MPN stem cell fitness and disease transplantability
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
RNA-Seq analysis - MPN vs. TAM
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
RNA-Seq analysis - MPN vs. TAM
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Phenotypic characterization and Jak2V617F oncogenic dependency in the setting of concomitant Tet2 loss
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Phenotypic characterization and Jak2V617F oncogenic dependency in the setting of concomitant Tet2 loss